Compositions and methods for the diagnosis and treatment of age-related macular degeneration
AssigneeGeorgetown University
InventorNady Golestaneh
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeorgetown University
InventorNady Golestaneh
Estimating the term…
The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) polymerase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-Iα) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-Iα or AKT3 and/or higher acetylation levels of PGC-Iα in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.
A method of determining if a subject is at risk of developing dry age-related macular degeneration (dry AMD), the method comprising
4-13. (canceled)
A method of monitoring the progression of dry age-related macular degeneration (dry AMD) in a subject, the method comprising
15-25. (canceled)
A method of reversing symptoms of dry age-related macular degeneration (dry AMD) in a subject in need of treatment thereof, the method comprising administering at least one of (i) a compound that induces expression or activity of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α) in retinal pigment epithelial cells;
31-34. (canceled) (Currently amended) The method of claim 26, wherein the PARP inhibitor is administered topically.
The method of claim 35, wherein the PARP inhibitor is comprised within a liquid composition.
Dependencies are inferred from the claim text.